Twitter Logo Youtube Circle Icon LinkedIn Icon

The Legal 500 Hall of Fame Icon The Legal 500 Hall of Fame highlights individuals who have received constant praise by their clients for continued excellence. The Hall of Fame highlights, to clients, the law firm partners who are at the pinnacle of the profession. In Europe, Middle East and Africa, the criteria for entry is to have been recognised by The Legal 500 as one of the elite leading lawyers for seven consecutive years. These partners are highlighted below and throughout the editorial.
Click here for more details

Israel > Healthcare and life sciences > Law firm and leading lawyer rankings


Index of tables

  1. Healthcare and life sciences
  2. Leading individuals

Who Represents Who

Find out which law firms are representing which Healthcare and life sciences clients in Israel using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact


Goldfarb Seligman & Co. fields 'a large, devoted team' with 'highly experienced partners in the field of healthcare and life sciences'. The team handles big-ticket M&A, litigation and a huge range of commercial collaboration and licensing agreements for multinational and growth-stage medical device and pharmaceutical companies. In a standout matter, the team advised EarlySense on several licensing and distributions agreements with companies in the US, including a rights agreements with Option Quant, which has exclusive rights agreements with the University of Chicago. Sharon Gazit, who heads the technology department, advises Elekta on the regulatory aspects of its distribution throughout Israel, and Ido Zemach acted for Syqe Medical in relation to a collaboration agreement with Teva Pharmaceutical Industries concerning an inhaler delivery system for medical cannabis. The firm also has a highly regarded M&A team, which advised Mitsubishi Tanabe Pharma Corporation on its acquisition of NeuroDerm, which was the largest-ever acquisition of an Israeli healthcare company. Other key clients include BrainsGate, NanoCell, and The Israeli Medical Association.

Herzog Fox & Neeman delivers 'reliable advice that is rooted in practical business experience'. It assists with joint venture and medical development arrangements, and also has a formidable regulatory practice advising HMOs, multinational healthcare companies and insurers. Zohar Yahalom has been noted in particular for his 'expertise in healthcare and life sciences regulation'. Yahalom has experience with commercial transactions, advises well-known domestic and multinational healthcare and pharmaceutical companies on a host of regulatory issues, and represents clients in business-critical licensing, distribution, and pricing matters before the Israeli courts. Also recommended is Dan Sharot, 'a service-oriented partner' with experience in IP matters in the healthcare industry and R&D collaboration agreements. Of note, Sharot advised Assured on its collaboration with Maccabi Health Services for the development of algorithmic software to analyse anonymised patient data with the aim of identifying patterns within the data sets. Another key figure is Neta Dorfman Raviv, who heads the insurance and financial institutions practice and advised Israeli Medical Association and The Zahal (IDF) Disabled Veterans Organization.

Horn & Co is known for providing top-quality service, particularly to pharmaceutical companies and investors, in relation to IP, commercial agreements, M&A and regulatory matters. The firm is also regularly involved in deals on the international stage, where is handles multinational R&D arrangements and advises global pharmaceutical companies on Israeli regulatory issues. In a standout matter, managing partner Yuval Horn and Keren Kanir advised Anima Biotech on a $1bn R&D agreement with Eli Lilly. Ohad Mamann acted for NTB Pharma in relation to an exclusive license agreement with New York University concerning an invention in the field of cancer immunotherapy. The team also has a prolific sector-focused corporate practice. Horn advises Pontifax Venture Capital Funds on new fund formation and all of its investment activities, and acts for a number of Israeli start-up and growth companies in relation to cross-border M&A and business transactions, capital markets offerings, and fund investments.

Lipa Meir & Co is 'a firm that makes things happen'. The healthcare and life sciences team has 'a vast clientele' ranging from HMOs to hospitals and service centres to medical device companies and clinical stage pharmaceutical companies. Led by Gary Copelovitz, the team acts for Clalit Health Services - Israel's largest HMO and the second largest HMO in the world - in a range of issues, including hospital contracts, disputes and administrative proceedings, and medical device tenders. Also of note, Copelovitz is advising Clalit on its role in a government programme for the genetic mapping of some 100,000 people for the establishment of a 'bio-bank'. Copelovitz is also engaged by Mor Research Applications, the tech-transfer arm of Clalit Health Services; here, the team regularly negotiates licensing agreements with multinational healthcare companies, and advises on various R&D, tech and big data issues. Other key figures include Roy Aiz and Yariv Shalom. Aiz regularly advises Nevo Medical on cross-border distribution agreements in the medical devices sector, and Shalom handles a range of regulatory and commercial issues for NARA Medical Center, which is Israel's largest private medical centre.

M. Firon & Co Advocates and Notaries is 'a first-rate team' with 'broad legal knowledge and a holistic approach', which enables the group to advise HMOs, pharmaceutical and medical device companies, start-ups and inventors, and medical centres on a wide range of commercial and regulatory matters. A key figure in the team is Baruch Shugol, who acts for a number of well-known multinational pharmaceutical companies, including GSK, and also assists Pharma Israel with ongoing regulatory issues and negotiations with government agencies. Shirley Dahan assists Israeli start-up companies in the biotech and medical device sectors with commercial agreements and investment rounds. Also recommended is Niv Sever, who is engaged by pharmaceutical and mature biotech companies, including Gilead Sciences. Other key clients include Geffen Medical, Clalit Health Services, and The Center for the Blind in Israel.

S. Horowitz & Co has a broad-based IP practice, with specialists in the life sciences and pharmaceutical industries advising on a host of regulatory matters and IP litigation as well as cross-border commercial, licensing and distribution agreements. Demonstrative of the practice's breadth, the team advises Teva Pharmaceutical Industries on an array of regulatory issues, including drug and medical device registration, clinical trials and genetic testing, pharmaceutical legislation, and drug patent disputes. Dovev Apel and Tal Band act for The Chemical, Pharmaceutical, and Environmental Society of the Manufacturer's Association of Israel in relation to regulatory negotiations, compliance and disputes involving animal testing, freedom of information, pricing and IP. Other significant clients include Dexcel, Shire International, Humacyte, Allergan, Genmab, and Novocure. Moreover, the team advises Yeda Research and Development, the tech-transfer arm of The Weizmann Institute of Science, and has also handled inbound and outbound licensing transactions for an Israeli med-tech company. Dr Asaf Rentsler is another key contact in the department, which has recently added a number of new partners through a combination of promotions and lateral hires.

Tadmor Levy & Co. is 'a truly excellent firm with specific expertise in the healthcare industry' and 'extensive knowledge of every possible regulatory hurdle' a client may face. A key figure in the team is Efrat Shapira-Orren, 'a bright, assertive and highly professional lawyer', who heads the firm's healthcare practice and also serves as chief counsel to Assuta Medical Centers, the largest chain of private hospitals in Israel. In this capacity, the team represents the client in regulatory and administrative procedures, and advises on issues including cross-border collaboration agreements, clinical trials, data and privacy laws, and relationships with physicians and insurers. Additionally, David Tadmor provides ongoing regulatory advice to SAREL Supplies & Services for Medicine, and the antitrust team advised an international pharmaceutical company on issues concerning its distribution arrangements. Also recommended is Elie Sprung, who regularly advises Israeli start-ups and growth companies in the healthcare sector on commercial and financing agreements.

Tulchinsky Stern Marciano Cohen Levitski & Co. acts for some of Israel's more promising med-tech, biotech and life sciences technology companies in significant commercial agreements and corporate matters; however, the firm's sector-expertise extends beyond the hi-tech space. Led by Menachem Tulchinsky, the department acts for one of Israel's largest healthcare logistics companies in relation to the distribution of pharmaceutical products and medical devices in cooperation with many of the world's largest multinational healthcare companies. Tulchinsky has also managed a significant regulatory approval for Nextar with regards to various R&D activities. In terms of product development and clinical trials, the team has experience drafting license, cooperation and clinical trial agreements with prestigious academic and research institutions in Israel, the US and Europe, including Johns Hopkins, UCLA, Charite Universitätsmedizin Berlin, and Università degli Studi of Rome. Additionally, the firm recently began advising The National Institute for Biotechnology in the Negev on its licensing and collaboration activities.

Yigal Arnon & Co brings together a very strong corporate practice and a highly specialised IP team to advise clients in the pharmaceutical, medical device and biotech sectors on a range of IP matters, inbound and outbound licensing, and complex M&A and cross-border investment transactions. Yoheved Novogroder-Shoshan advises FutuRx, a joint venture comprising Johnson & Johnson, Takeda and Orbimed, on pharmaceutical licensing transactions with universities and research institutions worldwide. Novogroder-Shoshan also assisted Alyn Hospital with the establishment of its Innovation Space. Also of note, Barry Levenfeld assisted with the formation of MEDX XELERATOR, a state-sponsored medical devices incubator, and provides the client with ongoing advice regarding commercialisation and arrangements among its partners and investors. Moreover, the firm's corporate team has been involved in a number of cross-border transactions in the biotech and healthcare sectors, which included acting for SteadyMed, the target company, in a reverse triangular merger with United Therapeutics Corporation. Other key figures include Daniel Green and Eli Greenbaum.

Amit, Pollak, Matalon & Co. Advocates and Notary has particular strengths in venture capital fund investment and hi-tech, and has been involved in major M&A, financing and commercialisation transactions in the healthcare and life sciences sectors. In a standout matter, department co-head Yoav Etzyon assisted a group of domestic and international investors with a $38m investment into Eloxx Pharmaceuticals, followed by a reverse triangular merger of Eloxx with Sevion Therapeutics. Maya Issacharov and Ian Rostowsky are key contacts for investment work; Issacharov helped establish a large investment fund and Rostowsky acts for aMoon in relation to its fund formation and investment activity. The team also acts for technology incubators, and handled a personal injury claim for a major pharmaceuticals company.

With notable strengths in corporate finance, IP, commercial licensing and M&A, Fischer Behar Chen Well Orion & Co is engaged by health funds and venture capital investors, growth companies, an international pharmaceutical company, and one of Israel's leading medical organisations. The healthcare and life sciences practice is jointly headed by Eran Yaniv and Raz Tepper, the latter of whom acted alongside Sharon Klein-Manbar to advise Perrigo Company on the sale of its active pharmaceutical ingredients business in Israel. Additionally, Yaniv handled corporate finance transactions for companies including Real Imaging Holdings, Nutrinia, Check-Cap, and Cannasoul Analytics. The team also advised Meuhedet Health Fund on its investment into NARA Medical Centers, and is engaged by investors such as OrbiMed Israel Partners.

Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co. advises venture capital investors and companies in the medtech, biotech and pharmaceuticals industries on corporate finance and investment mandates, licensing agreements, and other commercial development arrangements. Hili Cohen heads the department and has advised clients on licensing and collaboration agreements with universities and research centres. Also recommended is recently promoted partner Tami Fishman Jutkowitz, who assisted a pharmaceutical company with all the commercial agreements for the commencement of a phase of a clinical study. Further, the team has handled various finance transactions for companies including Orasis Pharmaceuticals, GI View and Kitov Pharmaceuticals, and also advises investors such as Korea Investment Partners and Quark Ventures.

Katzenell Dimant is a specialist firm representing hi-tech companies and venture capital investors, with a particular emphasis on the healthcare sector. Jointly headed by Ran Dimant and Einat Katzenell, the team advises healthcare-focused investment funds and companies in the biotech, pharmaceuticals and medical devices sectors on finance transactions and commercial agreements. Katzenell and Dimant have assisted SteadyMed since its time in incubation, handling all of the company's financing rounds and commercial agreements, and, in 2018, the team acted for the client in relation to its acquisition by United Therapeutics. Other key clients include Oncohost, Holon Institute of Technology, and Bar-Ilan Research & Development Company. On the investor side, the team does work for Citrine Biotech Fund and Joy Ventures.

Liad Whatstein & Co. Law Office is a high-quality IP boutique, which is regularly involved in IP disputes, particularly patent disputes, in the pharmaceuticals sector. Headed by Liad Whatstein, the team has handled complex disputes for many of the world's largest pharmaceutical companies, such as Merck, Pfizer, and Sanofi. Acting for Sanofi, the team is involved in a Supreme Court appeal concerning a District Court finding that the company committed fraud on the Patent Office. Further, Whatstein is representing Pfizer in a patent infringement proceeding against Unipharm concerning the client's drug, Viagra. Whatstein is also assisting Merck with ongoing opposition proceedings against Teva in relation to a diabetes drug. The team has also handled IP disputes for Novartis, Eli Lilly, and The State of Israel.

Meitar Liquornik Geva Leshem Tal Law Offices has 'a highly skilled team' with 'tremendous experience in successful corporate deals in the healthcare industry'. Additionally, the firm's top-tier litigation department represents pharmaceutical companies in a wide range of disputes, including high-profile product liability claims. For instance, Adv Ron Peleg is representing GSK Israel in a multimillion-dollar product liability claim filed by 40 individual plaintiffs. Acting alongside Adv Israel Leshem, Peleg is also representing Bayer Israel, Bayer Schering Pharma and Perrigo Israel Agencies in a matter concerning the companies' duty to provide patients with certain scientific information regarding possible side-effects. Also recommended are Adv Boaz Mizrahi and Adv Haim Gueta, who handle a range of financing transactions and commercial agreements for companies such as Gamida Cell and Ayala Pharmaceuticals; the duo also assist financiers such as Clal Biotechnologies Industries with investments into germinal healthcare-sector innovation companies.

From IP, to licensing and distribution, finance and acquisitions, and clinical trials, Pearl Cohen Zedek Latzer Baratz services the full spectrum of commercial needs for domestic and international clients in the healthcare and life sciences sector. The department is headed by Yael Baratz and Mark Cohen, the latter of whom splits his time between the firm's New York and Tel Aviv offices. Of note, Cohen is advising OPKO Biologics on agreements relating to its phase-III clinical trials across 80 sites globally. Additionally, Cohen assisted Ayala Pharmaceuticals with the establishment of a worldwide license agreement with Bristol-Myers Squibb. The team headed by Marcella Eytan, also advises Chiasma Inc on clinical trial-related agreements and documents for its phase III clinical trials in 17 countries worldwide. Moreover, the firm, which is perhaps best known for its IP capabilities, has helped build patent portfolios for pharmaceutical companies including Sanofi and Sol-Gel Technologies.

With strengths in investment and M&A transactions and complex IP commercialisation, Shibolet & Co. with Raved, Magriso, Benkel & Co. is 'a one-stop-shop' for hi-tech and growth companies in the healthcare sector, venture capital funds, and tech-transfer offices. Ofer Ben-Yehuda heads the practice and handles a litany of inbound licensing work for Trendlines Medical. The team has also negotiated high-value outbound licensing agreements. Moreover, Einat Weidberg is engaged by companies such as Galil Medical, NovoCure and Cartiheal, and also acts for R&D centres and incubators including Alon Medtec. Other key figures include Amir S. Iliescu and Tal Karplus, the latter of whom specialises in IP commercialisation and tech-transfer mandates.

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments in Israel

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

    Accredited investor funding platforms for innovative tech scale-ups offer more choice and without having to commit a large chunk of capital upfront, the risk is diluted.
  • Perhaps the QuadragaCX Story Will Have a Happy Ending

    While there are the aficionados who will say that cryptocurrencies will free us of the chains of the global financial institutions, on the occasions when the world of cryptocurrencies intersects with the world in which most of us live, the news is generally bleak. While you may not know one side of a Bitcoin from the other, you probably know that its value has crashed over the last 13 months, you may even have heard about some of some of the larger cryptohacks (that is computer heists through which digital currencies belonging to investors are stolen from crypto trading exchanges). And over the last week or so, you may have read on mainstream news sites about the death of Gerald Cotton the CEO of Canada‚Äôs largest cryptoexchange QuadragaCX. The death of the CEO of a company that few had previously heard of, was news of course, because in his passing he had taken the passwords to the accounts of his customers with him. The result of this being that about $140 million of their money was stuck somewhere between this world and the celestial ether in which Mr. Cotton now resides. Of course, it wasn‚Äôt quite told like that. We were fed terms such as ‚Äúprivate keys,‚ÄĚ lack of ‚Äúmulti-signature protection,‚ÄĚ ‚Äúcold storage wallets‚ÄĚ and more readily understandable ‚Äď ‚Äúcryptofraud‚ÄĚ. Again!
  • Israel Chapter in The Virtual Currency Regulation Review

    Earlier this year, the Israel Tax Authority (ITA) issued two circulars, one on the taxation of digital tokens and the second addressing the taxation of utility tokens in initial coin offerings (ICOs). Additionally, in March, the Israel Securities Authority (ISA) released a detailed interim report by the Committee for the Regulation of Public Offerings of Decentralized Cryptocurrency Coins (Report) (with a follow-up report due to come out around October 2018). Moreover, it is expected that before the end of 2018, legislation will come into force that for the first time will see Israeli primary legislation define virtual currencies as financial assets and mandate licensing for related services, as is later discussed in detail.
  • Spring is coming for real estate registration in Israel

    Israel may be the ‚ÄúStart-up Nation‚ÄĚ and a world-renowned center of technological innovation, yet for many years the procedures and conduct of the Israeli Land Registry have been trapped in the past.

    Israeli hi-tech and its sources of funding have grown and diversified tremendously since the bubble burst in 2001 and over the last decade since the height of the financial crisis in 2007-2008.

    Nondiscrimination has been the neglected stepchild of the FRAND commitment. Patent owners participating in standards organizations typically commit to license their technology on ‚Äúfair, reasonable, and nondiscriminatory (‚ÄúFRAND‚ÄĚ) terms.‚ÄĚ
  • Crash Course on Non-Disclosure Agreements

    Non-disclosure agreements are a crucial, but often overlooked, tool in allowing startup companies to grow, build strategic partnerships and explore new business relationships necessary to develop their product or bring it to market. These agreements are often short (sometimes only a page or two) and lead many founders to forego legal advice to get past this "formality" and begin working with the other party to the NDA. Yet, NDAs are important agreements with potentially far-reaching implications for the protection of a company's confidential information and intellectual property, and mishandling of NDAs can come back to haunt a startup years later.
  • Advocates Eli Greenbaum and Ezra Gross of Yigal Arnon & Co. in The Lawyer Special Report editorial

    An interview-style piece in The Lawyer, Law in Israel: moving beyond tech, quoting Eli Greenbaum and Ezra Gross:
  • Publication of Adv. Adrian Daniel's Commentary in Private Banker International on GDPR & Blockchain

    Publication of Adv. Adrian Daniel's Commentary in Private Banker International on GDPR & Blockchain.
  • Article in MEA Markets on GDPR & Israeli Law

    GDPR & ISRAELI PRIVACY LAW - KEY DIFFERENCES Yoheved Novogroder-Shoshan & Miriam Friedmann of Yigal Arnon & Co. outline the key differences between GDPR & Israeli Privacy Law.  mea_markets_-_gdpr__israeli_law_-_key_differences_14.05.2018

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to